Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161421 · ClinicalTrials.gov registry record · Phase 2
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00161421 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 18 participants.
The verdict
NCT00161421, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future. We will be administering three drugs. Dutasteride is FDA approved to treat prostate enlargement. Lupron is approved for treatment of prostate cancer. Testosterone is approved for treatment of testicular insufficiency. They are being used in this study for "off-label" research purposes. This study will allow us to find out the effect of food on two formulations of testosterone taken by mouth, and the relative effect of food on testosterone absorption. Information from this study may be useful in treatment of men with low testosterone levels and the development of a male hormonal contraceptive.
Interventions
- DRUG Dutasteride
- DRUG Oral Testosterone
- DRUG Leuprolide (Lupron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161421
The ClinicalTrials.gov registry entry for NCT00161421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dutasteride is the first listed.
NCT00161421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00161421 about?
NCT00161421 is a clinical study titled "Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone". The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future. We will be administering three drugs. Dutasteride is FDA approved to treat prostate en...
What is the current status of trial NCT00161421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00161421?
The interventions under investigation include: Dutasteride (DRUG), Oral Testosterone (DRUG), Leuprolide (Lupron) (DRUG).
Who is sponsoring clinical trial NCT00161421?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.